EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metabolic profiling and combined therapeutic strategies unveil the cytotoxic potential of selenium-chrysin (SeChry) in NSCLC cells

Cindy Mendes, Isabel Lemos, Ana Hipólito, Bruna Abreu, Catarina Freitas-Dias, Filipa Martins, Rita F Pires, Hélio Barros, Vasco D B Bonifácio, Luís G Gonçalves, Jacinta Serpa iD

Bioscience Reports · 31.07.2024 · 44 (7)

DOI: 10.1042/bsr20240752 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioscience Reports, online erschienen am 31.07.2024. Verfasst von Cindy Mendes und 10 weiteren Autor:innen. Beteiligte Einrichtung: iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Selenium. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e a Tecnologia (FCT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer ranks as the predominant cause of cancer-related mortalities on a global scale. Despite progress in therapeutic interventions, encompassing surgical procedures, radiation, chemotherapy, targeted therapies and immunotherapy, the overall prognosis remains unfavorable. Imbalances in redox equilibrium and disrupted redox signaling, common traits in tumors, play crucial roles in malignant progression and treatment resistance. Cancer cells, often characterized by persistent high levels of reactive oxygen species (ROS) resulting from genetic, metabolic, and microenvironmental alterations, counterbalance this by enhancing their antioxidant capacity. Cysteine availability emerges as a critical factor in chemoresistance, shaping the survival dynamics of non-small cell lung cancer (NSCLC) cells. Selenium-chrysin (SeChry) was disclosed as a modulator of cysteine intracellular availability. This study comprehensively characterizes the metabolism of SeChry and investigates its cytotoxic effects in NSCLC. SeChry treatment induces notable metabolic shifts, particularly in selenocompound metabolism, impacting crucial pathways such as glycolysis, gluconeogenesis, the tricarboxylic acid (TCA) cycle, and amino acid metabolism. Additionally, SeChry affects the levels of key metabolites such as acetate, lactate, glucose, and amino acids, contributing to disruptions in redox homeostasis and cellular biosynthesis. The combination of SeChry with other treatments, such as glycolysis inhibition and chemotherapy, results in greater efficacy. Furthermore, by exploiting NSCLC's capacity to consume lactate, the use of lactic acid-conjugated dendrimer nanoparticles for SeChry delivery is investigated, showing specificity to cancer cells expressing monocarboxylate transporters.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsSeleniumHumansMetabolomicsCell Line, TumorA549 CellsReactive Oxygen SpeciesFlavonoids

Stichwörter der Autor:innen

cancer metabolismlung cancermetabolic remodelingnew therapiesselenio-chrysin

Substanzen

SeleniumchrysinReactive Oxygen SpeciesFlavonoids

Autor:innen und Institutionen

  • iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisboa, Portugal.
  • Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof Lima Basto 1099-023, Lisboa, Portugal.
  • IBB - Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisbon, Portugal.
  • Department of Bioengineering, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisbon, Portugal.
  • Instituto de Tecnologia Química e Biológica António Xavier (ITQB NOVA), Avenida da República (EAN), 2780-157 Oeiras, Portugal.

ORCID-Profile: Jacinta Serpa

Förderung

  • Fundação para a Ciência e a Tecnologia (FCT)

Zitieren

APA

Mendes, C., Lemos, I., Hipólito, A., Abreu, B., Freitas-Dias, C., Martins, F., Pires, R. F., Barros, H., Bonifácio, V. D. B., Gonçalves, L. G., & Serpa, J. (2024). Metabolic profiling and combined therapeutic strategies unveil the cytotoxic potential of selenium-chrysin (SeChry) in NSCLC cells. Bioscience Reports, 44(7). https://doi.org/10.1042/bsr20240752

Vancouver

Mendes C, Lemos I, Hipólito A, Abreu B, Freitas-Dias C, Martins F, et al. Metabolic profiling and combined therapeutic strategies unveil the cytotoxic potential of selenium-chrysin (SeChry) in NSCLC cells. Bioscience Reports. 2024;44(7). doi:10.1042/bsr20240752

BibTeX
@article{Mendes2024,
  author = {Mendes, Cindy and Lemos, Isabel and Hipólito, Ana and Abreu, Bruna and Freitas-Dias, Catarina and Martins, Filipa and Pires, Rita F and Barros, Hélio and Bonifácio, Vasco D B and Gonçalves, Luís G and Serpa, Jacinta},
  title = {Metabolic profiling and combined therapeutic strategies unveil the cytotoxic potential of selenium-chrysin (SeChry) in NSCLC cells},
  journal = {Bioscience Reports},
  year = {2024},
  volume = {44},
  number = {7},
  doi = {10.1042/bsr20240752}
}
Kostenlos starten →